4'-O-methyldoxorubicin

RN given refers to parent cpd(L-lyxo)-(8S-cis)-isomer

Also Known As:

4'-O-methyldoxorubicin hydrochloride, (L-arabino)-(8S-cis)-isomer; 4'-O-methyldoxorubicin hydrochloride, (L-lyxo)-(8S-cis)-isomer; 4'-O-methyldoxorubicin, (L-arabino)-(8S-cis)-isomer

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 01/01/1981 - "Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin." 12/01/1980 - "The results of these studies indicate that: (a) the modifications in the chemical structure of doxorubicin can alter the biological properties and thus create new drugs varying in activity against different human tumors; (b) the two antracycline derivatives, 4'-deoxydoxorubicin and 4'-O-methyldoxorubicin, appear to be good candidates for clinical trial against colon carcinoma; and (c) the nude mice system can offer a great potential for identification of new anthracycline analogs and, in general, new anticancer agents of clinical interest."
2.	Leukemia P388 01/01/1981 - "In the present study, lines of P388 leukemia and Ehrlich ascites tumor with acquired resistance to doxorubicin were found to be cross-resistant to 4'-O-methyldoxorubicin, indicating that the natural and the acquired resistance to doxorubicin involve different mechanisms. " 01/01/1983 - "The most active compound against P388 leukemia was 4'-O-methyldoxorubicin, which was also more active than doxorubicin against L1210 leukemia."
3.	Ehrlich Tumor Carcinoma 01/01/1981 - "In vitro studies on the uptake of 4'-O-methyldoxorubicin in the Ehrlich ascites tumor cells indicated that the observed cross-resistance was partly due to a decreased drug uptake in the resistant cells because of an increased extrusion of the drug, in accordance with previous findings on the mechanism of acquired resistance to doxorubicin." 01/01/1981 - "In the present study, lines of P388 leukemia and Ehrlich ascites tumor with acquired resistance to doxorubicin were found to be cross-resistant to 4'-O-methyldoxorubicin, indicating that the natural and the acquired resistance to doxorubicin involve different mechanisms. "
4.	Carcinoma (Carcinomatosis) 12/01/1980 - "The results of these studies indicate that: (a) the modifications in the chemical structure of doxorubicin can alter the biological properties and thus create new drugs varying in activity against different human tumors; (b) the two antracycline derivatives, 4'-deoxydoxorubicin and 4'-O-methyldoxorubicin, appear to be good candidates for clinical trial against colon carcinoma; and (c) the nude mice system can offer a great potential for identification of new anthracycline analogs and, in general, new anticancer agents of clinical interest."
5.	Leukemia L1210 01/01/1981 - "A new analog of doxorubicin, 4'-O-methyldoxorubicin, was previously reported to have a pronounced activity against L1210 leukemia, which shows a natural partial resistance to doxorubicin itself. " 01/01/1983 - "The most active compound against P388 leukemia was 4'-O-methyldoxorubicin, which was also more active than doxorubicin against L1210 leukemia."

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Anthracyclines
3.	Antineoplastic Agents (Antineoplastics)
4.	esorubicin